 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
2007 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Application of mechanism-based population PKPD modelling in the rational selection of clinical candidates: an anti-IgE antibody example. | 3/16/2007 2:25:33 PM | Poster: Applications- Biologicals/vaccines | |
S. Albers (1), B. Meibohm (2), J. Barrett (3), TS. Mir (4), S. Laer (1) | Population Pharmacokinetics and Dose Simulation of Carvedilol in Pediatric Patients with Congestive Heart Failure | 3/27/2007 9:45:27 AM | Poster: Applications- CVS |
Sayar O.(1), Aldaz A. (1),Zufia L.(1), Viudez A.(2), Rifón J.(3), Nieto Y.(4) | New model for gemcitabine and its metabolites | 4/2/2007 11:44:45 AM | Poster: Applications- Oncology |
Aldaz A. (1), Sayar O. (1), Zufia L.(1), Viudez A.(2), Rifon J.(3), Nieto Y.(4) | Comparison between NONMEM and NPAG for gemcitabine modelling | 4/2/2007 11:39:39 AM | Poster: Applications- Oncology |
Setting a Safe Starting Dose for a First-in-Man trial of a Monoclonal Antibody Based on Population PK-PD Predictions | 3/30/2007 2:14:52 PM | Poster: Applications- Biologicals/vaccines | |
Antic, Julie (1,2) ; Chafaï, Djalil (1) ; Laffont, Céline (2) ; Concordet, Didier (1) | Evaluation of Non Parametric Methods for population PK/PD | 3/30/2007 7:53:58 PM | Poster: Methodology- Model evaluation |
Simultaneous Population Pharmacokinetic Modelling of Parent Compound and Metabolite in Plasma and Urine for a New Drug Candidate | 3/30/2007 10:53:59 AM | Poster: Methodology- Other topics | |
Jeffrey S. Barrett, Jeffrey Skolnik, Bhuvana Jayaraman, Dimple Patel, Peter Adamson | Improving Study Design and Conduct Efficiency of Event-Driven Clinical Trials via Discrete Event Simulation: Application to Pediatric Oncology | 2/17/2007 3:51:40 PM | Poster: Methodology- Design |
Advanced Population Analysis Features in the S-ADAPT/MCPEM Program | 3/29/2007 12:20:58 AM | Oral Presentation: Stuart Beal Methodology Session | |
Paul G Baverel, Radojka M Savic, Justin J Wilkins, Mats O Karlsson, | Evaluation Of The Nonparametric Estimation Method In NONMEM VI: Application To Real Data | 3/30/2007 7:44:09 PM | Poster: Methodology- Model evaluation |
Population design in nonlinear mixed effects multiple responses models: extension of PFIM and evaluation by simulation with NONMEM and MONOLIX | 3/30/2007 7:25:23 PM | Poster: Methodology- Design | |
Utility of a mixed effects approach to defining target binding rate constants. | 3/27/2007 12:23:39 PM | Poster: Applications- Other topics | |
Martin Bergstrand, Elodie Plan, Maria Kjellsson, Mats O Karlsson | A comparison of methods for handling of data below the limit of quantification in NONMEM VI | 3/31/2007 5:41:43 PM | Poster: Methodology- Other topics |
Influence of pharmacogenetic on pharmacokinetic interindividual variability of indinavir and lopinavir in HIV patients (COPHAR2 – ANRS 111 trial) | 3/30/2007 2:58:38 PM | Poster: Applications- Anti-infectives | |
Robert R. Bies1, Serge Guzy2, Joshua Sokoloski3, Laura Drewencki3, and Amy K. Wagner3. | An MCPEM approach to understanding inter-animal and inter-treatment changes with in vivo striatal dopamine clearance in rats. | 4/12/2007 5:52:27 PM | Poster: Methodology- Other topics |
Emma Boström, Margareta Hammarlund-Udenaes and Ulrika SH Simonsson | Blood-brain barrier transport helps explain discrepancies in in vivo potency between oxycodone and morphine | 3/27/2007 2:07:35 PM | Poster: Applications- CNS |
Normalized Prediction Distribution Error for the Evaluation of Nonlinear Mixed-Models | 3/15/2007 10:09:58 PM | Oral Presentation: Lewis Sheiner Student Session | |
A dedicated SAS Programming Group working in a pharmaceutical Modeling & Simulation organization - Current role, experience and prospects | 3/29/2007 2:54:36 PM | Poster: Applications- Other topics | |
Validation of statistically reliable biomarkers | 5/2/2007 10:29:02 AM | Tutorial | |
Modelling pharmacokinetic and pharmacodynamic properties of second generation antisense-oligonucleotides (ASOs). | 3/29/2007 11:53:20 PM | Poster: Methodology- Other topics | |
A model-based approach to dose selection in early paediatric development | 3/31/2007 8:08:43 PM | Poster: Methodology- Model evaluation | |
Comparison of uniresponse and multiresponse approaches of PopDes to optimize sampling times for drug-drug interaction studies: application to a Servier compound. | 3/30/2007 4:19:38 PM | Poster: Methodology- Design | |
Sau Yan Amy Cheung (1), James W. T. Yates (2), Oneeb Majid (3), Leon Aarons (4) | Identifiability Analysis and Parameter List Reduction of a Nonlinear Cardiovascular PKPD Model | 3/13/2007 3:57:19 PM | Oral Presentation: Lewis Sheiner Student Session |
Models of Glucose Metabolism and Control in Diabetes | 5/12/2007 3:16:12 PM | Oral Presentation: Applications | |
Emmanuelle Comets (1), Karl Brendel (2) and France Mentré (1,3) | Normalised prediction distribution errors in R: the npde library | 3/29/2007 12:35:14 PM | Poster: Methodology- Model evaluation |
How to estimate population variance matrices with a Prescribed Pattern of Zeros? | 3/29/2007 11:01:06 AM | Poster: Methodology- Other topics | |
Elimination of anti-epileptic compounds in Marseille aquatic environment from private hospital effluent - modelling versus measurements | 3/30/2007 1:57:28 PM | Poster: Methodology- Other topics | |
Insulin secretion and hepatic extraction during euglycemic clamp study: modelling of insulin and C-peptide data | 3/30/2007 11:37:42 AM | Oral Presentation: Model Building Session | |
Impact of handling missing PK data on PD estimation – explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions - a preclinical example. | 3/26/2007 7:09:32 PM | Oral Presentation: Applications | |
X Delavenne (1), T Basset (2), P Girard (3) , H Decousus (1,4), P Mismetti (1,4), S Laporte (1) | The use of an indirect response model to assess interaction between drugs: acenocoumarol and amoxicillin + clavulanic acid | 3/29/2007 9:50:43 AM | Poster: Applications- Coagulation |
Dickinson GL (1), Dawson M (2), Ward TH (2), Danson S (3), Ranson M (2), Dive C (2), Aarons L (1). | Population pharmacokinetics of a novel anticancer drug, RH1, in terminal cancer patients. | 3/30/2007 12:36:56 PM | Poster: Applications- Oncology |
An algorithm for proper lumping of systems of ODEs | 3/29/2007 5:58:17 PM | Poster: Methodology- Algorithms | |
Next-Generation Modeling Language | 2/19/2007 11:39:07 PM | Poster: Methodology- Other topics | |
Interspecies Population Modeling Of Pharmacokinetic Data Available At The End Of Drug Discovery | 3/8/2007 1:35:54 PM | Oral Presentation: Model Building Session | |
Automation of Structural Pharmacokinetic Model Search in NONMEM: Evaluation with Preclinical Datasets | 3/31/2007 12:05:11 AM | Poster: Methodology- Algorithms | |
D J Eleveld (1), J K G Wietasch (2), J H Proost (1), S Guzy(3), A Hoeft (4) | Is the expected performance of a target-controlled-infusion system influenced by the population analysis method | 2/28/2007 4:37:40 PM | Poster: Methodology- Model evaluation |
Iñaki F. Trocóniz (1), Raymond Miller (2), Mats O. Karlsson (3) | Modelling Overdispersion and Markovian Features in Count Data | 2/28/2007 4:46:36 PM | Poster: Methodology- Other topics |
M.A. Fabre (2), E. Fuseau (2), A. Vermeulen (1), A. Thyssen (1). | Population pharmacokinetic analysis in children, adolescents and adults with schizophrenia or bipolar disorder | 3/29/2007 10:43:47 AM | Poster: Applications- CNS |
Selection of a dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modelling. | 3/30/2007 2:01:26 PM | Poster: Methodology- Design | |
Marc-Antoine Fabre, Eliane Fuseau(1), Maria-Laura Sargentini-Maier, Nathalie Toublanc(2) | Retrospective population pharmacokinetic analysis of seletracetam in epileptic and healthy adults | 6/5/2007 7:55:45 PM | Poster: Applications- CNS |
A Physiologically Based Pharmacokinetic Model to Assess the Role of ABC Transporters in Drug Distribution | 1/31/2007 12:18:31 AM | Poster: Methodology- PBPK | |
Simulations of bioequivalence trials using physiological-pharmacokinetic models with saturable and non-saturable hepatic clearance | 3/30/2007 1:46:39 PM | Poster: Methodology- Model evaluation | |
Yumi Fukushima (1), Jean-Eric Charoin (1), Michael Brewster (2), E. Niclas Jonsson (1) | Population Pharmacokinetic Analysis of Trastuzumab (Herceptin®) based on Data from Three Different Dosing Regimens. | 3/29/2007 2:35:30 PM | Poster: Applications- Oncology |
An assessment of prediction accuracy of two IVIVC modelling methodologies. | 3/23/2007 2:33:08 PM | Poster: Methodology- Other topics | |
A population PK-PD method for categorical data analysis of progesterone antagonist activity in the rabbit McPhail’s model | 3/29/2007 2:56:20 PM | Oral Presentation: Model Building Session | |
Precision of Parameter Estimates: Covariance Step ($COV) versus Bootstrap Procedure | 3/28/2007 3:14:25 AM | Poster: Methodology- Model evaluation | |
Gibiansky E. (1), J. Janik (2), D. Mahony (2), K. Kaucic (1), L. Hammershaimb (1), G. Robbie (1). | Population Pharmacokinetics of Siplizumab (MEDI-507): Implications for Dosing | 3/30/2007 4:29:06 PM | Poster: Applications- Biologicals/vaccines |
Ihab G. Girgis, Vivek Viswanathan, Partha Nandy, and Surya Mohanty | Interactive Graphical Visualization Tool for Safety Data Screening | 3/30/2007 7:54:54 PM | Poster: Methodology- Other topics |
Ihab G. Girgis, Tom Schaible, Partha Nandy, Filip De Ridder, Jeffrey Mathers, and Surya Mohanty | Parallel Bayesian Methodology for Population Analysis | 3/27/2007 7:32:05 PM | Poster: Methodology- Other topics |
I. Grabnar(1), B. Faganel(2), V. Dolzan(3), A. Mrhar(1), J. Jazbec(2) | Population Pharmacokinetics of Methotrexate in Children with Lymphoid Malignancy | 3/31/2007 2:47:30 PM | Poster: Applications- Oncology |
The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process | 3/29/2007 10:35:57 PM | Poster: Methodology- Other topics | |
J. Grevel1, E. Fuseau1, C. Crepin1, M. Vernaz-Gris1, M. Marchand1, D. Huntjens2 | Evaluation of the population pharmacokinetic properties of lidocaine and its metabolites, MEGX, GX, and 2,6-xylidine, after application of lidocaine 5% medicated plaster. | 5/10/2007 11:01:04 AM | Poster: Applications- Other topics |
A Population PK/PD Model Assessing The Pharmacodynamics Of A Rapid-Acting Recombinant FVII Analogue, NN1731, In Healthy Male Subjects | 3/31/2007 1:23:23 PM | Poster: Applications- Coagulation | |
Prospective application of a multivariate population optimal design to determine parent and metabolite pharmacokinetic sampling times in a Phase II study. | 3/30/2007 6:41:41 PM | Poster: Methodology- Design | |
Combining interoccasion variability and mixture within a MCPEM framework | 1/30/2007 11:21:48 PM | Poster: Methodology- Other topics | |
Comparison between NONMEM and the Monte-Carlo Expectation Maximization (MC-PEM) Method Using a Physiologically-Based Glucose-Insulin Model | 4/5/2007 6:36:00 PM | Poster: Methodology- Algorithms | |
E.K. Hansson(1), M. Sandström(2), H. Lindman(3), L.E. Friberg(1) | Modelling of Chemotherapy-induced Febrile Neutropenia using the Predicted Degree and Duration of Myelosuppression | 3/30/2007 3:45:00 PM | Poster: Applications- Oncology |
Estimation of patient compliance from pharmacokinetic samples | 3/31/2007 11:32:41 AM | Poster: Methodology- Other topics | |
Tobramycin in paediatric CF patients - TCI or “One dose fits all” | 3/30/2007 7:51:14 AM | Poster: Applications- Anti-infectives | |
Pharmacokinetic-pharmacodynamic modeling of manganese in patients with acute alcoholic hepatitis after an IV infusion of mangafodipir. | 3/30/2007 11:01:28 AM | Poster: Applications- Other topics | |
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. | 3/28/2007 9:20:24 AM | Poster: Applications- Anti-infectives | |
Almond L1, Rowland Yeo K1, Howgate EM1, Tucker GT1,2, Rostami-Hodjegan A1,2 | Mechanistic Prediction of HIV Drug-Drug Interactions in Virtual Populations from in vitro Enzyme Kinetic Data: Ritonavir and Saquinavir. | 3/30/2007 4:14:00 PM | Poster: Applications- Other topics |
Pankaj Gupta, Matthew M Hutmacher, Bill Frame and Raymond Miller | A new approach for population pharmacokinetic data analysis under noncompliance | 3/30/2007 4:16:11 AM | Poster: Methodology- Other topics |
Bojan Lalovic, Matthew M Hutmacher, Bill Frame, Kaori Ito, Raymond Miller | Modeling the Dropout from Longitudinal Adverse Event Data: Selecting Optimal Titration Regimens | 3/30/2007 4:30:04 AM | Poster: Applications- CNS |
Comparing Minimum Hellinger Distance Estimation (MHDE) and Hypothesis Testing to Traditional Statistical Analyses – a Simulation Study | 3/30/2007 8:47:18 PM | Poster: Methodology- Other topics | |
Population PK/PD of Alprazolam in the Attenuation of ACTH Activation Induced by Cognitive Performance in Metyrapone-treated Healthy Volunteers | 3/30/2007 7:05:10 PM | Poster: Applications- CNS | |
Philippe Jacqmin (1), Lynn McFadyen (2) and Janet R. Wade (1) | Basic PK/PD principles of proliferative and circular systems | 3/31/2007 11:43:23 AM | Oral Presentation: Applications |
R Jelliffe, A Schumitzky, D Bayard, R Leary, M Van Guilder, A Gandhi, M Neely, and A Bustad. | The USC*PACK collection of BigWinPops software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software | 4/4/2007 3:58:15 AM | Software demonstration |
A Population Model of Epidural Lidocaine | 2/6/2007 10:50:56 PM | Poster: Applications- Other topics | |
P. Johnson (1), H. Dai (2), S. Neelakantan (2), T. Tensfeldt (2) | Optimal dose & sample-size selection for dose-response studies | 3/29/2007 5:25:33 PM | Poster: Methodology- Design |
Pharmacokinetic modelling of the once-daily human glucagon-like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatide | 3/30/2007 2:57:02 PM | Poster: Applications- Endocrine | |
Kristin E. Karlsson(1), Justin Wilkins(1,3), Mats O. Karlsson(1) and E. Niclas Jonsson(1,2) | Modelling of disease progression in acute stroke by simultaneously using the NIH stroke scale, the Scandinavian stroke scale and the Barthel index | 3/31/2007 8:39:37 AM | Oral Presentation: Applications |
RJ Keizer(1), E van Twuijver(2), JJ Marcar(2), PFW Strengers(2), ADR Huitema(1) | Bioequivalence study of a C1-esterase-inhibitor product (Cetor®) with optimised sampling design | 3/31/2007 8:37:00 PM | Poster: Applications- Biologicals/vaccines |
Hui Kimko, Steven Xu, Bindu Murthy, Mahesh Samtani, Partha Nandy, Richard Strauss, Gary Noel | Population Pharmacokinetic Analysis To Support Dosing Regimens Of Ceftobiprole | 5/1/2007 3:57:35 PM | Poster: Applications- Anti-infectives |
Maria C. Kjellsson (1), Daniele Ouellet (2), Raymond Miller (2), Mats O. Karlsson (1) | Modelling Sleep Using Markov Mixed Effects Models | 3/30/2007 4:20:06 PM | Poster: Applications- CNS |
Population Pharmacokinetic Model for Human Growth Hormone in Adult Patients in Chronic Dialysis vs. Healthy Subjects | 5/3/2007 4:31:45 PM | Poster: Applications- Endocrine | |
Can Bayes Prevent QTC-interval prolongation? A challenge beyond random effects. | 3/29/2007 3:28:45 PM | Poster: Applications- CVS | |
Pharmacodynamic Modelling of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects | 3/29/2007 6:28:51 PM | Poster: Applications- Biologicals/vaccines | |
K. Kuester(1,3), A. Kovar(2), B. Brockhaus(2), C. Kloft(1,3) | Matuzumab – A Population Pharmacokinetic Model and its Evaluation | 3/19/2007 3:08:33 PM | Poster: Applications- Oncology |
Population pharmacokinetic analysis of perindoprilat in hypertensive paediatric patients | 3/30/2007 4:39:18 PM | Poster: Applications- CVS | |
Lemenuel-Diot A., Laffont C.M. , Jochemsen R., Foos-Gilbert E. | Evaluation of model of Heart Rate during Exercise Tolerance Test with missing at random dropouts | 5/21/2007 10:04:56 AM | Poster: Methodology- Model evaluation |
PLS Chan, E van Schaick, G Langdon, J Davis, T Parkinson, L McFadyen | PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor | 3/30/2007 4:53:54 PM | Poster: Applications- Anti-infectives |
Non-Linear Mixed Effects PK/PD Modelling of Acute Autoinhibitory Feedback Effects of Escitalopram (ESC) on Extracellular Serotonin (5-HT) Levels in Rat Brain | 3/31/2007 6:18:28 PM | Poster: Applications- CNS | |
The SAEM algorithm and its implementation in MONOLIX 2.1 | 3/31/2007 8:42:33 AM | Oral Presentation: Stuart Beal Methodology Session | |
An evolutonary nonparametric NLME algorithm | 3/26/2007 4:23:03 PM | Poster: Methodology- Algorithms | |
R. Lledó-García (1), M. Merino Sanjuán (1), L. Prats (1), A. Nácher (1), V.G. Casabó (1) | Population Pharmacokinetics of Saquinavir in rats after IV and IP administration. An approach to Saquinavir/Ritonavir Pharmacokinetic interaction. | 3/25/2007 12:43:44 PM | Poster: Applications- Anti-infectives |
PK/PD modeling of Adinazolam – effect of variability of absorption, PK and PD parameters on variability in PD response | 3/30/2007 12:04:28 AM | Poster: Applications- Other topics | |
Predicting human from animal PBPK simulation combined with in vitro data | 4/4/2007 7:50:18 PM | Poster: Methodology- PBPK | |
Mathilde Marchand (1, 2), Eliane Fuseau (1), David Critchley (3) | Supporting the recommended paediatric dosing regimen for rufinamide using clinical trial simulation | 4/4/2007 7:29:42 PM | Poster: Applications- CNS |
Population PKPD modelling of biomarkers ANP and big ET-1 for two neutral endopeptidase inhibitors | 3/30/2007 1:52:16 PM | Poster: Methodology- Model evaluation | |
Population Pharmacokinetics of Rimonabant in Obesity | 4/12/2007 1:52:00 PM | Poster: Applications- Endocrine | |
Sensitivity analysis of a mixture model to determine genotype/phenotype | 3/28/2007 6:54:06 PM | Poster: Methodology- Other topics | |
L. McFadyen (1), P. Jacqmin (2), J. Wade (2), B. Weatherley (1) | Maraviroc Exposure Response Analysis: Phase 3 Antiviral Efficacy in Treatment Experienced HIV+ Patients | 3/30/2007 6:58:31 PM | Poster: Applications- Other topics |
Pharmacokinetics / Pharmacodynamics of Intravenous Bolus Nicardipine in Adults Undergoing Cardiovascular Surgery | 3/30/2007 9:57:31 PM | Poster: Applications- CVS | |
Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison | 3/30/2007 7:41:37 PM | Oral Presentation: Methodology | |
Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(2) | Semi-mechanistic PKPD model for neutropenia using K-PD model in patients receiving high dose of chemotherapy | 3/31/2007 11:46:51 PM | Poster: Applications- Oncology |
Population Pharmacokinetics of Aplidin® (plitidepsin) in Subjects with Cancer | 3/31/2007 8:09:33 PM | Poster: Applications- Oncology | |
Impact of Lopinavir Limit of Quantification (LOQ)-Censored Data Replacement on Population Pharmacokinetic (PK) Plasma and Saliva Modeling in HIV-Infected Children | 3/13/2007 1:01:24 AM | Poster: Methodology- Model evaluation | |
What Additional Information Can we Retrieve When Compliance is Accounted For? An explicit Compliance-Pharmacokinetic Formalism | 1/30/2007 3:54:40 PM | Oral Presentation: Stuart Beal Methodology Session | |
A. Russu (1), M. Neve (2), G. De Nicolao (1), I. Poggesi (2), R. Gomeni (2) | Population methods for dose escalation studies: an MCMC approach | 3/30/2007 7:35:17 PM | Poster: Methodology- Design |
A Comparison of Estimation Methods in Nonlinear Mixed-effect Model for Population Pharmacokinetic-pharmacodynamic Analysis | 3/23/2007 3:29:40 PM | Poster: Methodology- Other topics | |
Ng CM (1), Bauer RJ (2), Beeram M (1), Takimoto CH (1), Lin C (1), Patnaik A (1) | A Systematical Approach to Bridge the Two-Stage Parametric Expectation Maximization Algorithm and Full Bayesian Three-Stage Hierarchical Nonlinear Mixed Effect Methods in Complex Population Pharmacokinetic/Pharmacodynamic Analysis: Troxacitabine-induced Neutropenia in Cancer Patients | 3/30/2007 4:10:45 AM | Poster: Methodology- Other topics |
A Bayesian approach for the integration of preclinical information into a PBPK model for predicting human pharmacokinetics | 3/30/2007 4:54:56 PM | Poster: Methodology- PBPK | |
Population pharmacokinetic modelling of pimozide and its relation to CYP2D6 genotype. | 3/30/2007 7:29:56 PM | Poster: Applications- CNS | |
Sequential versus simultaneous optimal experimental design on dose and sample times | 3/30/2007 4:37:19 PM | Oral Presentation: Methodology | |
Sample Size Calculations for Repeated Binary Population Pharmacodynamic Experiments | 3/30/2007 2:27:13 PM | Poster: Methodology- Design | |
The performance of model selection criteria in the absence of a fixed-dimensional correct model | 3/31/2007 2:16:21 PM | Poster: Methodology- Model evaluation | |
Calcium Homeostasis and Bone Remodeling: Development of an Integrated Model for Evaluation and Simulation of Therapeutic Responses to Bone-Related Therapies | 4/13/2007 6:36:18 AM | Poster: Applications- Other topics | |
Semiparametric distributions with estimated shape parameters: Implementation and Evaluation | 3/30/2007 5:26:30 PM | Poster: Methodology- Model evaluation | |
Marcella Petrone, Stefano Zamuner, Vincenzo Di Iorio, Roger Gunn, Marc Laruelle and Roberto Gomeni | Model-based sequential human PET study design for Optimal PK/RO assessment | 3/30/2007 8:02:19 PM | Poster: Methodology- Design |
Optimal Sampling Design and Trial Simulation using POPT and NONMEM | 4/8/2007 2:44:25 AM | Poster: Methodology- Design | |
Investigation of performances of FOCE and LAPLACE algorithms in NONMEM VI in population parameters estimation of PK and PD continuous data | 3/30/2007 3:26:22 PM | Poster: Methodology- Algorithms | |
Teun Post(1), Tomoo Funaki(2), Hiromi Maune(2), Henk-Jan Drenth(1) | Circadian rhythm in pharmacodynamics and its influence on the identification of treatment effects | 3/26/2007 11:12:46 AM | Oral Presentation: Applications |
Dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling. | 3/14/2007 6:23:00 PM | Poster: Applications- Other topics | |
Modeling of plasma aldosterone concentrations after prokinetic 5-HT4 receptor agonists: forming an integrated simulation framework for summary statistic and subject-level data. | 4/17/2007 10:48:56 AM | Poster: Applications- Endocrine | |
E.H. Cox (1)(3), N.H. Prins (1), G. D’Souza (2) & L. McFadyen (2) | Integrated Modeling & Simulation of Clinical Response and Drop-out of D2 receptor agonists in Patients with Early Parkinson’s Disease. | 4/22/2007 10:30:12 AM | Oral Presentation: Applications |
Dittberner, S. (1), V. Duval (2), A. Staab (2), I. Troconiz (3), U. Graefe-Mody (2), U. Jaehde (1) | Determination of the absolute bioavailability of BI 1356, a substance with non-linear pharmacokinetics, using a population pharmacokinetic modelling approach | 3/28/2007 9:20:18 PM | Poster: Applications- Endocrine |
S. Retout (1, 2), C. Bazzoli (1), E. Comets (1), H. Le Nagard (1), F. Mentré (1, 2) | Population designs evaluation and optimisation in R: the PFIM function and its new features | 3/30/2007 4:55:00 PM | Poster: Methodology- Design |
Ribba B., Tod M., Girard P., You B., Mercier C., Vassal G., Freyer G., Tranchand B. | ODE solvers and stiffness issues for complex population PK models | 3/30/2007 12:24:24 PM | Poster: Methodology- Algorithms |
Stefaan Rossenu (1), Clare Gaynor (2), An Vermeulen (1), Adrian Dunne (2) and Adriaan Cleton (1) | A mixture distribution approach to IVIVC modeling of a dual component drug delivery system | 3/30/2007 10:11:32 AM | Poster: Methodology- Other topics |
David Salinger and the Resource Facility for Population Kinetics (RFPK) | The System for Population Kinetics (SPK) | 6/1/2007 6:45:59 PM | Software demonstration |
Mahesh N. Samtani, Juan Jose Perez-Ruixo, Kathryn Brown, Dirk Cerneus, Christopher Molloy | PK/PD Model of Pegylated Thrombopoietin Mimetic Peptide in Healthy Subjects: Comparison of Verification Procedures for Assessing Model Predictability. | 4/20/2007 6:01:50 PM | Poster: Methodology- Model evaluation |
Comparing treatment effect in depression trials: Mixed Model for Repeated Measures vs Linear Mixed Model | 3/30/2007 1:20:29 PM | Poster: Applications- CNS | |
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics and Estimation: Problems and Solutions | 3/16/2007 11:31:45 AM | Oral Presentation: Lewis Sheiner Student Session | |
Planning To Communicate | 3/29/2007 12:27:32 AM | Oral Presentation: Applications | |
A pharmacokinetic/pharmacodynamic model to determine optimal dosing targets for amikacin in neonatal sepsis | 3/30/2007 1:32:41 AM | Poster: Applications- Other topics | |
Population Pharmacokinetic Modeling Of Busulfan In Patients Undergoing Autologous Stem Cell Transplantation (ASCT) For Multiple Myeloma | 3/29/2007 9:29:44 AM | Poster: Applications- Oncology | |
How can routinely collected comedication information from phase II/III trials be used for screening of potential effects on model parameters? A case study with the oral direct thrombin inhibitor Dabigatran etexilate | 3/29/2007 3:24:07 PM | Poster: Methodology- Other topics | |
JF Standing (1,2), RF Howard (1,3), A Johnston (4), I Savage (2), ICK Wong (1,2,3) | Developmental Pharmacokinetics of Diclofenac for Acute Pain | 3/15/2007 10:26:46 PM | Oral Presentation: Applications |
Population pharmacokinetics of certolizumab pegol | 3/23/2007 2:19:27 PM | Poster: Applications- Biologicals/vaccines | |
Dose-response population modeling of the new antiepileptic drug brivaracetam in add-on treatment of partial onset seizures. | 3/23/2007 1:46:17 PM | Poster: Applications- CNS | |
Strougo, A(1), Elassaiss-Schaap, J(2), de Greef, HJMM(2), Drenth, H(1) | Mechanism-based model of the effect of co-administration of exogenous testosterone and progestogens on the hypothalamic-pituitary-gonodal axis in men | 3/23/2007 11:24:03 AM | Oral Presentation: Applications |
Kim Stuyckens, Stefaan Rossenu, Peter King, Janine Arts, Juan Jose Perez-Ruixo. | Modeling Drug Effects and Resistance Development on Tumor Growth Dynamics | 3/30/2007 9:43:48 PM | Oral Presentation: Applications |
A Comparison of Fixed Dose-Controlled (FD) versus Pharmacokinetic Modified Dose-Controlled (PKMD) Clinical Study Designs | 3/30/2007 10:28:06 PM | Poster: Methodology- Other topics | |
Steady-state Equation for the Bicompartmental Model with Gamma Absorption. Application to Mycophenolate PK in Renal Transplant Patients | 2/7/2007 2:30:51 PM | Poster: Methodology- Other topics | |
M. Vernaz-Gris (1), E. Fuseau (1), L. Del Frari (2), V. Brunner (2), P. Hermann (2) | Pooled PK analysis of a new CNS drug, in healthy subjects. | 3/29/2007 5:32:02 PM | Poster: Applications- CNS |
Modeling the time-course of the antipyretic effects and prostaglandin inhibition in relation the analgesic effects of naproxen: a compound selection strategy | 3/31/2007 1:52:25 PM | Poster: Applications- CNS | |
K. Vucicevic(1), B. Miljkovic(1), M. Pokrajac (1), I. Grabnar(2) | Population Pharmacokinetic Modelling of Amitriptyline in Depression Patients | 3/31/2007 4:36:39 PM | Poster: Applications- CNS |
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Inter-Occasion Variability and Level and Type of Information Provided | 3/30/2007 6:27:44 PM | Poster: Applications- Oncology | |
A flexible approach to modeling variable absorption in the context of repeated dosing: illustrated with rifampicin | 3/29/2007 9:18:32 AM | Oral Presentation: Methodology | |
Kinetic models of PSA decrease after surgery in prostate tumor diseases as a help for clinician interpretation | 3/29/2007 11:47:43 AM | Oral Presentation: Applications | |
Optimal Design to Estimate the Time Varying Receptor Occupancy Relationship in a PET Experiment | 3/26/2007 2:43:39 PM | Oral Presentation: Methodology | |
Phase I study design of indisulam: evaluation and optimization | 3/31/2007 2:02:07 AM | Poster: Methodology- Design | |
Dose individualization of indisulam to reduce the risk of severe myelosuppression | 3/31/2007 2:07:03 AM | Poster: Applications- Other topics |
